Century Therapeutics is no longer the oncology cell-therapy story that listed on Nasdaq, and the equity now prices a funded but still preclinical bet that an engineered islet product can do what two company-sponsored trials of the first candidate did not: produce a result large enough to reset the franchise. The company spent 2025 walking away from a Bristol-Myers Squibb collaboration, shutting the lymphoma study of its natural-killer candidate, and then discontinuing its own autoimmune trial of the same product, before naming a type 1 diabetes islet program as the new lead and raising a large private placement against that claim. At about $1.86, with a market value near $337 million, the shares sit well above the year-low print and above net cash after leases, so the tape is already paying a nine-figure enterprise premium for a platform that has yet to put the new lead into humans. The debate is whether that premium is cheap convexity on a functional diabetes cure or payment for a serial pivot that has already consumed most of the original public-company thesis.
The financing that reset the balance sheet is the event that makes the new story investable at all. In January the company sold common stock, pre-funded warrants, and accompanying warrants to a syndicate led by TCGX, with RA Capital, Commodore, Deep Track, RTW, Venrock, and the T1D Fund in the book, for about $135 million of gross proceeds and roughly $126 million net. The unit price of $1.15, plus a half-warrant struck at $2.60, more than doubled the common share count from the year-end base. That year-end count sat near 88 million, and the attached warrants keep another large block hanging over the register until either early clinical data on the islet program arrive or three years pass. The structure bought a stated cash runway into early 2029 and a specialist-capital endorsement of the diabetes turn, but it also locked in dilution as the price of survival after the partner exit.
The tension is that the same year that produced the raise also produced a retreat from company-sponsored clinical work. The natural-killer product remains in a German investigator-sponsored basket under Professors Georg Schett and Andreas Mackensen, after five patients in the company-run autoimmune study and a discontinued lymphoma cohort. Safety in those settings looked clean, with no dose-limiting toxicities and no high-grade cytokine or neurologic events reported in the company-run cohort, yet management still chose to stop spending on its own trial and to concentrate cash on a product that has not entered the clinic. A reader who treats the raise as proof of platform strength is ignoring the revealed preference: when forced to choose, the company stopped writing checks for the only product that has actually been infused into patients.
What resolves the argument is not another expense cut. It is whether the Food and Drug Administration accepts an investigational application for the islet candidate in the fourth-quarter window management has kept on the calendar after a pre-submission meeting that produced alignment on toxicology, manufacturing release tests, and a Phase 1/2 design, and whether that product then shows persistence without chronic immunosuppression. Until those two facts exist, the equity is a cash-funded option on a manufacturing and editing hypothesis, and the warrant overhang is the market's own reminder of how much additional paper that syndicate already owns.